Safety and efficacy of cefpirome in comparison with ceftazidime in chinese patients with sepsis due to bacterial infections

Chemotherapy

Volumn 46, Issue 5, 2000, Pages 371-378

  Fang, Chi Tai ^a   Chen, Yee Chun ^b   Lin, Seng Fong ^a   Shau, Wen Yi ^b   Liu, Chieh Ju ^a   Sheng, Wang Huei ^b   Wang, Jen Tay ^a   Chang, Shan Chwen ^b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cefpirome; Ceftazidime; Efficacy; Safety; Sepsis

Indexed keywords

CEFPIROME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENTEROBACTER INFECTION; FEMALE; GASTRITIS; HUMAN; KLEBSIELLA PNEUMONIAE; LIVER; MALE; MICROBIOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS;

ADULT; AGED; CEFTAZIDIME; CEPHALOSPORINS; ESCHERICHIA COLI INFECTIONS; EXANTHEMA; FEMALE; GASTRITIS; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; LIVER; MALE; MIDDLE AGED; SEPSIS;

EID: 0034267558     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007311     Document Type: Article

References (34)

1. Norrby SR, Dotevall L, Eriksson M, Efficacy and safety of cefpirome (HR 810). J Antimicrob Chemother 1988;22:541-547.
2. Jones RN, Thornsberry C, Barry AL, In vitro evaluation of HR 810, a new wide-spectrum aminothiazolyl a-methoxyimino cephalosporin. Antimicrob Agents Chemother 1984; 25:710-718.
3. ChengAF,LingTK,LamAW,Fung KS, Wise R, The antimicrobial activity and beta-Iactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents. J Antimicrob Chemotherl993;31:699-709.
4. Bergeron MG, Bernier M, Bactericidal activity of cefpirome (HR 810) against 513 gram-negative bacteria isolated from blood of septicémie
5. patients. Infection I994;22:299305.
6. Limbert M, Seibert G, Winkler I, Isert D, Kiesel N, Markus A, Schrinner E, Antibacterial activity in vitro of cefpirome against clinical isolates causing sexually transmitted diseases. J Antimicrob Chemother 1992;29(supplA):13-17.
7. Fernandas C, Pritchard R, Morris A, Benn R, In vitro evaluation of cefpirome: An Australasian study of isolates from intensive care unit and hematology/oncology patients. The Cefpirome Study Group. Diagn Microbiol Infect Dis 1998;31:493-495.
8. Hoogkamp-Korstanje JA, Verduyn Lunel F, Meis JF, Cefpirome: Epidemiological survey in intensive care units and hematological units in The Netherlands. The Dutch Study Group. Diagn Microbiol Infect Dis I998;31:489-491.
9. Pierard D, Emmerechts K, Lauwers S, Comparative in vitro activity of cefpirome against isolates from intensive care and haematology/oncology units. Belgian Multicentre Study Group. J Antimicrob ChemotherI998;41:443-450.
10. Reeves DS, Bywater MJ, Holt HA, The activity of cefpirome and 10 other antibacterial agents against 2858 clinical isolates collected from 20 centres. J Antimicrob Chemother 1993;31:345-362.
11. Yoshimura H, Kosaka Y, Hayashi T, Kawahara S, The antimicrobial activity in vitro of cefpirome and 6 other beta-lactam antibacterial agents against clinical isolates. Jpn J Antibiot 1993;46:877-883.
12. Liassine N, Bille J, Breer C, Frei R, Wust J, Auckenthaler R, In vitro activity of cefpirome against microorganisms isolated in haematology, oncology and intensive care units in Switzerland. Scand J Infect Dis 1997;29:615-621.
13. Spencer RC, Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group. Scand J Infect Dis Suppl 1993;91: 25-32.
14. Paradis D, Vallée F, Allard S, Bisson C, Daviau N, Drapeau C, Auger F, LeBel M, Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob Agents Chemother I992;36:2085-2092.
15. Sader HS, Jones RN, In vitro antimicrobial activity of cefpirome against ceftazidime-resistant isolates from two multicenter studies. Eur J Clin Microbiol Infect Dis 1994;13:675-679.
16. Watanabe N, Hiruma R, Katsu K:, Comparative in vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeniginosa. J Antimicrob Chemother 1992;30:633-641.
17. Piacentini E, Amalfitano G, Ligozzi M, Canepari P, Fontana R, In vitro activity of cefpirome (HR 810) against enterococci and staphylococci. J Chemother 1992;4:338-341.
18. Barry AL,B,rownSD,NovickWJ, In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates. Antimicrob Agents Chemother 1995;39:21932196.
19. Fremaux A, Sissia G, Spicq C, Geslin P, In vitro activity of cefpirome against Streptococcus pneumoniae strains with decreased susceptibility to cefotaxime. Diagn Microbiol Infect Dis 1998;31:501-502.
20. Spangler SK, Jacobs MR, Appelbaum PC, Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother 1994; 38:898-900.
21. Cefpirome versus ceftazidime in the treatment of urinary tract infections. J Antimicrob Chemother 1992;29(supplA):95-104.
22. Norrby SR, Cefpirome: Efficacy in the treatment of urinary and respiratory tract infections and safety profile. Scand J Infect Dis Suppl 1993; 91:41-50.
23. Carbon C, Prospective randomized phase II study of intravenous cefpirome 1 gor2gbd in the treatment of hospitalized patients with different infections. Cefpirome Study Group. J Antimicrob Chemother 1992; 29(suppl A):87-94.
24. Norrby SR, Geddes AM, Shah PM, Cefpirome versus ceftazidime as empirical sepsis treatment. The Cefpirome Study Group. Diagn Microbiol Infect Dis 1998;31:499-500.
25. Norrby SR, Geddes AM, Shah PM, Randomized comparative trial of cefpirome versus ceftazidime in the empirical treatment of suspected bacteraemia or sepsis. Mutlicentre Study Group. J Antimicrob Chemother!998;42:503-509.
26. Wolff M, Comparison of strategies using cefpirome and ceftazidime for empiric treatment of pneumonia in intensive care patients. The Cefpirome Pneumonia Study Group. Antimicrob Agents Chemother 1998; 42:28-36.
27. Norrby SR, Geddes AM, Efficacy of cefpirome in the treatment of septicaemia. Scand J Infect Dis Suppl I993;91:51-59.
28. Donaubauer HH, Mayer D, Toxicity of cefpirome: An overview. J Antimicrob Chemother 1992;29 (supplA):71-73.
29. Ferguson GC, Nunn AJ, Fox W, Miller AB, Robinson DK, Tall R, A second international co-operative investigation into thiacetazone sideeffects. Rashes on two thiacetazonecontaining regimens. Tubercle 1971;52:166-181.
30. Ellard GA, The potential clinical significance of the isoniazid acethylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 1984;65:211-227.
31. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ, Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989;320: 565-570.
32. Blood pressure studies in 14 communities. A two-stage screen for hypertension. JAMA 1977;237:23852391.
33. Weir MR, Gray JM, Paster R, Saunders E, Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicenter Study Group. Hypertension 1995;26:124-130.
34. Brown NJ, Ray WA, Snowden M, Griffin MR, Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996;60:8-13.